Brain inflammation targeted in first Dementia Consortium drug discovery project
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
List view / Grid view
22 June 2015 | By Victoria White
The Dementia Consortium is funding a new project to target the immune system in the hunt for new treatments for Alzheimer's disease...
11 June 2015 | By Victoria White
Researchers have identified a naturally occurring variant of the human prion protein that produces resistance to prion diseases such as CJD...
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
9 June 2015 | By Victoria White
A new study has revealed that calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, may also protect against Alzheimer’s disease...
26 March 2015 | By Victoria White
New treatments, diagnostics and medical technologies are set to benefit from an investment of £32 million through the Biomedical Catalyst...
9 March 2015 | By Edinburgh Research and Innovation
University of Edinburgh spin-out company Parkure Ltd has successfully attracted over £75,000 in crowdfunding investment through ShareIn, the technology-focussed crowdfunding firm, to develop a cure for Parkinson’s disease...
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
9 October 2014 | By On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the…
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...